Fotemustine in the Treatment of Brain Primary Tumors and Metastases

Khayat, David; Giroux, B.; Bérille, J.; Cour, V.; Gerard, B.; Sarkany, Marlis; Bertrand, P.; Bizzari, Jean-Pierre

doi:10.3109/07357909409038234

Cited by 63 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Exposure to carcinogens plays an etiological role in the initiation of breast cancer. Organophosphorous compounds are of great interest because of the extensive use in agriculture, medicine and industry (8)(9)(10)(11). Such compounds are the most widely used pesticides by virtue of their biodegradable nature and short persistence.…”

Section: Introductionmentioning

confidence: 99%

Cell adhesion proteins altered by 17β estradiol and parathion in breast epithelial cells

Calaf¹,

Roy²

2008

Oncol Rep

View full text Add to dashboard Cite

Abstract. The association between breast cancer initiation and prolonged exposure to estrogen suggests that this hormone may also have an etiologic role in such a process. On the other hand, many studies have found an association between human cancer and exposure to agricultural pesticides such as parathion, an organophosphorous pesticide used in agriculture to control mosquito plagues. However, the key factors behind the initiation of breast cancer remain to be elucidated. The aim of this study was to determine the effect of 17ß estradiol (estrogen) and parathion on protein expression in cell transformation of human breast epithelial cells in vitro. Estrogen and parathion alone and in combination induced malignant transformation of an immortalized human breast epithelial cell line, MCF-I0F, as indicated by anchorage independency and invasive capabilities. The results indicate that a combination of estrogen and parathion increased the expression of related cell adhesion proteins such as Dvl, Notch, CD146 and ß catenin. In conclusion, it can be suggested that pesticides affect human breast cell adhesion changes indicative of transformation.

show abstract

Section: Introductionmentioning

confidence: 99%

Cell adhesion proteins altered by 17β estradiol and parathion in breast epithelial cells

Calaf¹,

Roy²

2008

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…IL-2-based regimens have also not demonstrated efficacy in the CNS [2,18]. There are some sporadic reports of chemotherapy with or without radiotherapy with activity in cerebral metastases from melanoma [19]. Radiotherapy alone may offer some palliation of symptoms for patients with brain metastases, but there is no evidence that survival is prolonged [19].…”

Section: Discussionmentioning

confidence: 97%

The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma

et al. 2004

View full text Add to dashboard Cite

Cerebral metastases from melanoma are correlated with a poor prognosis. Temozolomide is an oral alkylating agent that can cross the blood-brain barrier and in phase II and III trials, patients with advanced metastatic melanoma achieved overall response rates of 13 to 21%. The present study evaluated the efficacy and toxicity of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma. Twenty-five patients (median age 48 years) with histologically confirmed stage IV melanoma and cerebral metastases treated with temozolomide-based chemotherapy. 10 patients received temozolomide plus docetaxel, nine patients temozolomide plus cisplatin and six patients temozolomide as single agent. Six patients achieved an objective response (24%). All responses were partial. The disease was stable in five patients (20%) and 13 patients progressed (52%). The median response duration was 6.9 months (range 1.8 to 16 months). The median time to progression (TTP) for all patients was 2 months, compared with a median TTP of 3.9 months, among responders and a median TTP of 1.8 months, for patients who remained stable or progressed (P<0.0001). The median survival time for the entire patient population was 4.7 months. The median survival for responders was 5.5 months and for non-responders was 3.6 months. The difference was statistically significant (P<0.05). The toxicity was mild. The most frequently reported adverse event were myelotoxicity and nausea and vomiting. Four patients developed grade 3/4 leukopenia, two grade 4 neutropenia, and one patient developed grade 3 thrombocytopenia. There was no treatment discontinuation caused by toxicity. Temozolomide-based chemotherapy may have a role in patients with cerebral metastases from melanoma. Further exploration is required. Toxicity was manageable.

show abstract

“…Systemic therapy options include chemo-and immunotherapy, alone or in combination. A greater antitumour effect of chemotherapy in metastatic melanoma is seen with dacarbazine (DTIC), with an 8-20% response rate (RR), most of them partial response (PR), and a median duration of response of 4-6 months [1][2][3], temozolamide, with similar RR [4,5], platinum analogues, with a 15-20% RR [1], nitrosureas, with a 13-18% RR [1,2,6], and antimicrotubule agents, with modest activity [1]. Single-agent cytotoxic chemotherapy with DTIC is the standard care in normal practice, although the RR is generally low and few patients attain complete remission.…”

Section: Introductionmentioning

confidence: 99%